Elsevier

Maturitas

Volume 71, Issue 2, February 2012, Pages 94-103
Maturitas

Review
Chronic kidney disease and diabetes

https://doi.org/10.1016/j.maturitas.2011.11.009Get rights and content

Abstract

Chronic kidney disease has a significant worldwide prevalence affecting 7.2% of the global adult population with the number dramatically increasing in the elderly. Although the causes are various, diabetes is the most common cause of CKD in the United States and an increasing cause of the same worldwide. Therefore, we chose to focus on diabetic chronic kidney disease in this review.

The pathogenesis is multifactorial involving adaptive hyperfiltration, advanced glycosylated end-product synthesis (AGES), prorenin, cytokines, nephrin expression and impaired podocyte-specific insulin signaling. Treatments focus on lifestyle interventions including control of hyperglycemia, hypertension and hyperlipidemia as well treatment of complications and preparation for renal replacement therapy. This review examines the current literature on the epidemiology, pathogenesis, complications and treatment of CKD as well as possible areas of future disease intervention.

Introduction

Chronic kidney disease (CKD) affects a significant portion of the world population with a prevalence of 7.2% in adults over age 30 and dramatically increasing to 23.4–35.8% over age 65 [1]. Furthermore, population based studies in the United States reveals a CKD prevalence ranging from 1.4 to 43.3% [2]. The causes of CKD are various and include glomerular kidney disease, tubular and interstitial kidney disease, obstructive uropathy, pre renal and vascular disorders, diabetes and hypertension. Globally, diabetes is the most common cause of CKD.

There are multiple etiologies involved in the pathogenesis of diabetic CKD. The initial mechanism of damage involves adaptive hyperfiltration which leads to long term damage of functioning nephrons. Additional mechanisms of disease include advanced glycosylated end products (AGEs), vascular endothelial growth factor (VEGF), prorenin and the renin–angiotensin system, cytokines, nephrin expression and impaired podocyte signaling. Importantly, CKD is associated with an increased risk of cardiovascular disease, mortality and end stage renal disease. Most patients are likely to die than develop end stage renal disease. Treatments are limited but focus on treatment of associated causes including diabetes and hypertension, slowing progression of disease, treatment of complications and preparation for renal replacement therapy. This review examines the current literature on the epidemiology, pathogenesis, complications and treatment of CKD as well as possible areas of future disease intervention.

Diabetes mellitus is a disease that affects over 23.5 million American adults [3] and type 2 diabetes accounts for over 90% [4], [5]. Diabetes is the most common cause of CKD. The prevalence of some degree of CKD among adults with type 2 diabetes is 40% [3], [6], [7], [8], [9], [10], [11]. The 2009 annual report published by the United States Renal Data Systems, reports the prevalence rate of CKD in type 2 diabetes according to stage was 8.9% for stage I, 12.8% for stage II, 19.4% for stage III, and 2.7% for stages IV and V combined. The lifetime risk of developing CKD in type 1 diabetes is 25% [5], [12], [13], [14], [15], [16], [17].

The older population is especially affected by diabetic nephropathy. The incidence of end stage renal disease (ESRD) related to diabetes among the elderly markedly increased from the 1980s up until the late 1990s at which time there was slight decrease and leveling off to approximately 350–370/100,000 [4], [18], [19]. This more recent decline in CKD is likely due to earlier recognition and interventions.

In the 2010 Annual report published by the United States Renal Data Systems, the median age of incident ESRD population was 64.2 in 2008 which varied by race; the median age ranged from 59.2 among African Americans to 66.8 among whites. The rate of prevalence of CKD remains highest among the African American and Native American population, and lowest among the Caucasian and Asian population paralleling the rate of diabetes in these populations [20], [21]. The trend of increasing prevalence is expected to continue to grow as the elderly population continues to rise with increased life expectancy.

CKD in diabetes causes significant disability and contributes greatly to health care costs; annually approaching $23 billion with ESRD in the US [22]. McFarlane et al. [23] evaluated the risk of hospitalization, cardiovascular risk and death in patients with chronic kidney disease and reported that the adjusted risk of hospitalization increased as the estimated glomerular filtration rate (eGFR) decreased ranging from an increase of 14% with an estimated GFR of 45 to 59 ml/min/1.73 m2 to an increase of 315% with an estimated GFR of less than 15 ml/min/1.73 m2.

Section snippets

Diabetic nephropathy

CKD is defined as progressive, irreversible loss in kidney function. The National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (K/DOQI) defined CKD as lasting three or more months with either kidney damage defined by structural or functional abnormalities of the kidney with or without decreased eGFR, or a GFR of less than 60 ml/min/1.73 m2. These abnormalities include markers of kidney damage [1] such as albuminuria, abnormal urinary sediment (casts, epithelial cells),

Diet, weight reduction, exercise and smoking

Epidemiological studies reveal a relationship between lifestyle variables including diet, obesity, exercise and smoking and CKD. However, evidence of benefit is limited as there are few robust intervention studies [90], [91], [92], [93], [94], [95], [96], [97], [98].

The diet recommended is low protein and low carbohydrate diet. In the early stages of CKD, protein intake should not exceed 0.8–1.0 g kg/wt d, while in later stages of CKD protein should be limited to 0.8 g kg/wt d. Dietary restriction

Conclusions

The incidence of chronic kidney disease in diabetes continues to rise. This is especially true in the elderly population. CKD progresses from glomerular hyperfiltration to overt diabetic nephropathy. Microalbuminuria may not always progress to ESRD and conversely declining renal function may occur in the absence of declining GFR. Its pathogenesis is multifactorial including factors such as AGES, pro-renin, cytokines, nephrin expression, impaired podocyte signaling, changes in the

Contributors

All authors contributed equally to this manuscript.

Competing interests

There are no competing interests except M. Banerji. Mary Ann Banerji speakers Bureau – Merck, Amylin, Sanofi-Aventis, Boehringer-Ingleheim Advisory Boards; Data Monitoring Committees – Boehringer-Ingleheim, Novartis; BMS Research Grants – Merck, Boehringer-Ingleheim, Roche.

Provenance and peer review

Commissioned and externally peer reviewed.

References (149)

  • N. Ismail et al.

    Renal disease and hypertension in non-insulin-dependent diabetes mellitus

    Kidney Int

    (1999)
  • S. Rudberg et al.

    Increased glomerular filtration rate as a predictor of diabetic nephropathy—an 8-year prospective study

    Kidney Int

    (1992)
  • A. Benigni et al.

    Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy

    Kidney Int

    (2004)
  • D. Daneman et al.

    Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents

    Kidney Int

    (1994)
  • D. Leehey et al.

    Role of angiotensin II in diabetic nephropathy

    Kidney Int

    (2000)
  • U. Brewster et al.

    The renin–angiotensin–aldosterone system and the kidney: effects on kidney disease

    Am J Med

    (2004)
  • P. Kalra et al.

    Haemoglobin concentration and prognosis in new ccases of heart failure

    Lancet

    (2003)
  • L. Fried et al.

    Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals

    J Am Coll Cardiol

    (2003)
  • I. Lopez et al.

    Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo

    Kidney Int

    (2011)
  • D. Andress

    Adynamic bone in patients with chronic kidney disease

    Kidney Int

    (2008)
  • M. Alikhani et al.

    Advanced glycation endproducts stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways

    Bone

    (2007)
  • V. Panichi et al.

    Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium

    Kidney Int

    (1998)
  • K. Iseki et al.

    Body mass index and the risk of development of end-stage renal disease in a screened cohort

    Kidney Int

    (2004)
  • M. Boyce et al.

    Exercise training by individuals with predialysis renal failure: cardiorespiratory endurance, hypertension and renal function

    Am J Kidney Dis

    (1997)
  • Center for Disease Control and Prevention. Diabetes data and trends....
  • Center for Disease Control and Prevention. National diabetes fact sheet; 2007....
  • J. New et al.

    Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general population

    Diabetes Med

    (2007)
  • E. Ritz et al.

    Nephropathy in patients with Type 2 diabetes mellitus

    N Engl J Med

    (1999)
  • L. Plantinga et al.

    Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes

    CJSAN

    (2010)
  • C. Alleyn et al.

    Occurrence of microalbuminuria in young people with Type 1 diabetes: importance of age and diabetes duration

    Diabetes Med

    (2010)
  • M. Caramori et al.

    The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

    Diabetes

    (2000)
  • P. Hovind et al.

    Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study

    BMJ

    (2004)
  • B. Perkins et al.

    Microalbuminuria and the risk for early progressive renal function decline in Type 1 diabetes

    J Am Soc Nephrol

    (2007)
  • J. Steinke et al.

    Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients

    Pediatr Endocrinol Rev

    (2008)
  • T. Zelmanovitz et al.

    Diabetic nephropathy

    Diabetol Metab Synd

    (2009)
  • Center for Disease Control and Prevention. Incidence of ESRD Among Persons with Diabetes – United States, 1990–2002....
  • Excerpts from United States Renal Data System-2009 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage...
  • L.C. Platinga et al.

    CDC CKD surveillance team, association of CKD with disability in the United States

    Am J Kidney Dis

    (2011)
  • A. Go et al.

    Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

    N Engl J Med

    (2004)
  • A. Levey et al.

    A new equation to estimate glomerular filtration rate

    Ann Int Med

    (2009)
  • A. Levey et al.

    National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

    Ann Intern Med

    (2003)
  • K. Rossing

    Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring

    Dan Med Bull

    (2007)
  • C. Hasslacher et al.

    Diabetic nephropathy in type II diabetes: effect of metabolic control and blood pressure on its development and course

    Dtsch Med Wochenschr

    (1987)
  • M. Ravid et al.

    Main risk factors for nephropathy in Type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia

    Arch Intern Med

    (1998)
  • M. Williams

    The goal of blood pressure control for prevention of early diabetic microvascular complications

    Curr Diabetes Rep

    (2011)
  • UK Prospective Diabetes Study (UKPDS) Group

    Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

    Lancet

    (1998)
  • J. Alwakeel et al.

    Factors affecting the progression of diabetic nephropathy and its complications: a single-center experience in Saudi Arabia

    Ann Saudi Med

    (2011)
  • M. Goldschmid et al.

    Diabetes in Urban African-Americans. II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes

    Diabetes Care

    (1995)
  • A. Varghese et al.

    Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India

    Postgrad Med J

    (2001)
  • C. Mogensen

    Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

    N Engl J Med

    (1984)
  • Cited by (72)

    • A preliminary study on health impacts of Mexican mercury mining workers in a context of precarious employment

      2022, Journal of Trace Elements in Medicine and Biology
      Citation Excerpt :

      Similarly, Global Burden Disease estimates, establish diabetes along with chronic renal injury as the second cause of death in Mexico until 2017 [89]. It should be noted that 17.6 % of mining workers have diabetes and the damage that manifests itself can be derived from that pathology [90]. However, about 42 % of workers already have some parameters altered to be considered prediabetic, which may act as risk factors in these people for presenting renal alterations [86].

    View all citing articles on Scopus
    View full text